Vaxcyte (NASDAQ:PCVX) CAO Sells $182,760.00 in Stock

Posted by Brenda Bartman on Nov 7th, 2026

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.92, for a total value of $182,760.00. Following the completion of the transaction, the chief accounting officer owned 27,860 shares in the company, valued at $1,697,231.20. This represents a 9.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan also recently made the following trade(s):

On Monday, October 5th, Elvia Cowan sold 19,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total transaction of $1,648,060.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $63.89 on Friday. The business has a 50-day simple moving average of $61.71 and a two-hundred day simple moving average of $57.32. Vaxcyte, Inc. has a fifty-two week low of $40.14 and a fifty-two week high of $90.75.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same period in the previous year, the company earned ($1.56) earnings per share. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -7.47 earnings per share for the current fiscal year.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. Allworth Financial LP increased its holdings in Vaxcyte by 18.4% during the third quarter. Allworth Financial LP now owns 1,521 shares of the company’s stock worth $88,000 after buying an additional 236 shares during the last quarter. New York Life Investment Management LLC increased its stake in shares of Vaxcyte by 19.7% in the 3rd quarter. New York Life Investment Management LLC now owns 21,011 shares of the company’s stock valued at $1,196,000 after purchasing an additional 3,451 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Vaxcyte by 6.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,808 shares of the company’s stock worth $438,000 after acquiring an additional 444 shares during the last quarter. Candriam S.C.A. increased its holdings in shares of Vaxcyte by 115.0% in the third quarter. Candriam S.C.A. now owns 447,260 shares of the company’s stock valued at $25,542,000 after purchasing an additional 239,206 shares during the period. Finally, Covestor Ltd grew its position in shares of Vaxcyte by 31.1% in the third quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after purchasing an additional 223 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

PCVX has been the topic of several recent analyst reports. Needham & Company LLC raised their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Bank of America dropped their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Finally, Guggenheim upped their price target on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.50.

Read Our Latest Research Report on PCVX

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.